LIQ865

LIQ865 is an investigational injectable, sustained‑release formulation of the long‑acting amide local anesthetic bupivacaine, developed using Liquidia’s PRINT microparticle technology to provide prolonged postoperative local analgesia while reducing the need for opioids.[1][4][7][12] It consists of distinct particulate formulations (LIQ865A and LIQ865B) engineered to release bupivacaine over several days at the site of administration, with Phase 1 trials demonstrating local anesthetic pharmacodynamic effects and acceptable safety in healthy volunteers.[2][4][7][11][12][14] The product is being developed by Liquidia Technologies for management of local post‑surgical pain, aiming to deliver three to five days of pain control following procedures such as bunionectomy.[1][4][7][8][11][14]